Iovance Biotherapeutics(IOVA) - 2022 Q3 - Quarterly Report

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 75-3254381 825 Industrial Road, Suite 400, San Carlos, CA 94070 (Address of principal executive offices and zip code) (650) 260-7120 (Registrant's telephone number, includi ...